Iliac Artery DiseaseNCT02698358
Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)
An observational study of Iliac Artery Disease, run by Yonsei University at 1 site in South Korea.
Trial summary
Prospective, single-arm, multi-center registry study A total of 150 subjects with iliac artery disease who meet all inclusion and exclusion criteria will be included. Patients will be followed clinically for 12 months after the procedure. Read more about this study
- Who is it for?
- Ages 19 to 85 years
- Conditions the study is for
- Iliac Artery Disease
- What is being tested?
- Epic stent (Boston Scientific)
- Type of treatment
- Medical device
- How many people
- 68 participants
- Where
- 1 siteSouth Korea
- Study dates
- Dec 2015to Jan 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Iliac artery disease
Who may be able to join
- Age 19 years of older
- Symptomatic peripheral artery disease:
- Moderate or severe claudication (Rutherford category 2 or 3)
- Critical limb ischemia (Rutherford category 4)
- Iliac artery lesions with stenosis > 50%
- ABI <0.9
- Patients with signed informed consent
Who cannot join
- Acute critical limb ischemia
- Severe critical limb ischemia (Rutherford category 5 or 6)
- Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents
- In-stent restenosis lesions (Restenosis lesions without previously implanted stents are eligible to the enrollment)
- Bypass graft lesions
- Age > 85 years
Show all 12Show fewer
- Severe hepatic dysfunction (> 3 times normal reference values)
- Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
- LVEF < 40% or clinically overt congestive heart failure
- Pregnant women or women with potential childbearing
- Life expectancy <1 year due to comorbidity
- Untreated proximal inflow disease of aorta or the ipsilateral iliac arteries (more than 50% stenosis or occlusion)
Trial locations and contacts
1 site in 1 country.
About this study
- Prospective, single-arm, multi-center registry study
- A total of 150 subjects with iliac artery disease who meet all inclusion and exclusion criteria will be included.
- Patients will be followed clinically for 12 months after the procedure.
- Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months.
- Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months.
- Quality of life by standardized questionnaires (at baseline \& at 1 \& 12 months)
- Conditions
- Iliac Artery Disease
- Being tested
- Epic stent (Boston Scientific)
- Keywords
- Peripheral artery disease, Iliac artery, nitinol stent, restenosis
- Medical subject headings
- Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Epic stent (Boston Scientific)Device
| Study group | Role | What they receive |
|---|---|---|
| K-EPIC | Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific). Receives: Device: Epic stent (Boston Scientific) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary patency
Absence of restenosis >50% based on an imaging study (Duplex ultrasound, CT angiography or catheter angiography) at 12 months
Measured: 12 months
Secondary outcomes (3)
Target lesion revascularization rate
Measured: 12 months
Stent fracture rate
Measured: 12 months
Quality of life by standardized questionnaires
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2016 (estimated)
- Study startDec 2015
- Primary completionJan 2021 (estimated)
- Study completionJan 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Iliac Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02698358
- Sponsor's protocol ID
- 1-2015-0075
- Status last verified
- Jan 2019
- First submitted
- 29 Feb 2016
- Last updated
- 29 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)
- ClinicalTrials.gov ID
- NCT02698358
- Acronym / sponsor ID
- 1-2015-0075
- Conditions
- Iliac Artery Disease
- Keywords
- Peripheral artery disease, Iliac artery, nitinol stent, restenosis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- Jan 2021 (estimated)
- Study completion
- Jan 2021 (estimated)
- First posted
- 3 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Prospective, single-arm, multi-center registry study
- A total of 150 subjects with iliac artery disease who meet all inclusion and exclusion criteria will be included.
- Patients will be followed clinically for 12 months after the procedure.
- Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months.
- Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months.
- Quality of life by standardized questionnaires (at baseline \& at 1 \& 12 months)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| K-EPIC | – | Device: Epic stent (Boston Scientific)Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific). |
Who may qualify
- Ages
- 19 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Iliac artery disease
Key inclusion criteria (7 listed)
- Age 19 years of older
- Symptomatic peripheral artery disease:
- Iliac artery lesions with stenosis > 50%
- ABI <0.9
- Patients with signed informed consent
Key exclusion criteria (12 listed)
- Acute critical limb ischemia
- Severe critical limb ischemia (Rutherford category 5 or 6)
- Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents
- In-stent restenosis lesions (Restenosis lesions without previously implanted stents are eligible to the enrollment)
- Bypass graft lesions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Epic stent (Boston Scientific) | Device | K-EPIC |
Primary outcome
Primary patency
Time frame: 12 months
Absence of restenosis >50% based on an imaging study (Duplex ultrasound, CT angiography or catheter angiography) at 12 months
3 secondary outcomes
Target lesion revascularization rate
Time frame: 12 months
Stent fracture rate
Time frame: 12 months
Quality of life by standardized questionnaires
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2019.
- Individual participant dataSharing planned: No
Related trials for Iliac Artery Disease
Active, not recruitingObservational study
External Iliac Artery Endofibrosis in Cycling
Iliac Artery Occlusive Disease, Blood Flow Velocity
Active, not recruitingObservational study
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Peripheral Artery Disease, Popliteal Aneurysm
Recruiting
iHub Stent-Graft for Iliac Artery Aneurysms: Safety, Performance, and Effectiveness Study
Iliac Aneurysm, Aortic Aneurysm, Abdominal
RecruitingObservational study
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study
Peripheral Arterial Disease, Aortoiliac Occlusive Disease
RecruitingObservational study
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)
Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Iliac Artery Disease, run by Yonsei University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary patency (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2019.